Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02880956 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease

A Phase 2 study of Alzheimers Disease, sponsored by AbbVie.

Completed
Registry status
Phase 2
Development phase
453
Enrollment target
20
Study locations

NCT02880956 is a Phase 2 study of Alzheimers Disease that has completed, run by AbbVie. The registered enrollment target is 453 participants, below the 4,058-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02880956, a Phase 2 study of Alzheimers Disease, has completed, sponsored by AbbVie.

COMPLETED
Registry status
Phase 2
Development phase
453 participants
Enrollment target
20
Study locations

Study Summary

This study seeks to evaluate the efficacy and safety of ABBV-8E12 in participants with early Alzheimer's disease (AD).

Conditions Studied

Alzheimers Disease

Interventions

  • DRUG ABBV-8E12
  • DRUG placebo for ABBV-8E12

Study Locations (20)

Florida

  • Brain Matters Research /ID# 147796 - Delray Beach
  • Neuropsychiatric Research Center of Southwest Florida /ID# 162332 - Fort Myers
  • Mayo Clinic /ID# 151236 - Jacksonville
  • Synexus Clinical Research US, Inc. /ID# 147804 - Orlando
  • University of South Florida /ID# 151890 - Tampa
  • Synexus Clinical Research US, Inc /ID# 151633 - The Villages

California

  • Irvine Clinical Research /ID# 162331 - Irvine
  • Ucsd /Id# 152467 - La Jolla
  • Ray Dolby Brain Health Center /ID# 154965 - San Francisco
  • Univ California, San Francisco /ID# 152053 - San Francisco

Georgia

  • Emory Midtown Infectious Disease Clinic /ID# 151492 - Atlanta
  • Atlanta Center for Medical Research /ID# 151550 - Atlanta
  • NeuroStudies.net, LLC /ID# 152746 - Decatur

Illinois

  • Great Lakes Clinical Trials /ID# 152754 - Chicago
  • Advocate Lutheran General Hospital /ID# 152052 - Park Ridge
  • Southern IL Univ School of Med /ID# 151769 - Springfield

Arizona

  • Banner University of Arizona Medical Center Phoenix /ID# 151536 - Phoenix
  • Banner Sun Health Res Inst /ID# 151895 - Sun City

Indiana

  • Indiana University /ID# 151861 - Indianapolis

Kansas

  • University of Kansas Medical Center - Alzheimer's Disease Center /ID# 151554 - Fairway

Trial Details

FieldValue
Enrollment Target 453 participants
Start Date 2017-01-26
Est. Completion 2021-07-28
Phase Phase 2

Sponsor

AbbVie

526 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02880956

The ClinicalTrials.gov registry entry for NCT02880956 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 453 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,058-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (89% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which ABBV-8E12 is the first listed.

NCT02880956 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT02880956 about?

NCT02880956 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease". This study seeks to evaluate the efficacy and safety of ABBV-8E12 in participants with early Alzheimer's disease (AD).

What is the current status of trial NCT02880956?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 453 participants. The study started on 2017-01-26. Estimated completion is 2021-07-28.

What conditions does trial NCT02880956 study?

This clinical trial studies the following conditions: Alzheimers Disease.

What interventions are being tested in trial NCT02880956?

The interventions under investigation include: ABBV-8E12 (DRUG), placebo for ABBV-8E12 (DRUG).

Who is sponsoring clinical trial NCT02880956?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02880956 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimers Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimers Disease

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.